PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24856644-11	2014	Taken together, the present results confirm that simvastatin inhibition of platelet activation is mediated by PPARgamma-dependent processes, which involves mediating MAPKs signaling, increase of cAMP formation and VASP Ser(157) phosphorylation, inhibition of Akt phosphorylation and intracellular Ca(2+) mobilization.	Simvastatin	49-60	vasodilator stimulated phosphoprotein	Homo sapiens	214-218	
20525309-10	2010	Simvastatin markedly increased NO release, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) expression.	Simvastatin	0-11	vasodilator stimulated phosphoprotein	Homo sapiens	43-80	
20525309-10	2010	Simvastatin markedly increased NO release, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) expression.	Simvastatin	0-11	vasodilator stimulated phosphoprotein	Homo sapiens	82-86	
20525309-11	2010	SQ22536, an inhibitor of adenylate cyclase, markedly reversed the simvastatin-mediated inhibitory effects on platelet aggregation, PLCgamma2 and p38 MAPK phosphorylation, and simvastatin-mediated stimulatory effects on VASP and eNOS phosphorylation.	Simvastatin	66-77	vasodilator stimulated phosphoprotein	Homo sapiens	219-223	
24856644-9	2014	Moreover, in the presence of GW9662, simvastatin-mediated increase of cyclic adenosine monophosphate (cAMP) production, vasodilator-stimulated phosphoprotein (VASP) Ser(157) phosphorylation and inhibition of Akt phosphorylation were markedly reversed.	Simvastatin	37-48	vasodilator stimulated phosphoprotein	Homo sapiens	159-163